Fulvestrant
| Clinical data | |
|---|---|
| Pronunciation | /fʊlˈvɛstrənt/ fuul-VES-trənt |
| Trade names | Faslodex, others |
| Other names | ICI-182780; ZD-182780; ZD-9238; 7α-[9-[(4,4,5,5,5-Pentafluoropentyl)-sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17β-diol |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607031 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intramuscular injection |
| Drug class | Antiestrogen |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Low |
| Protein binding | 99% |
| Metabolism | Hydroxylation, conjugation (glucuronidation, sulfation) |
| Elimination half-life | IM: 40–50 days |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.170.955 |
| Chemical and physical data | |
| Formula | C32H47F5O3S |
| Molar mass | 606.78 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.
Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.
Fulvestrant was approved for medical use in the United States in 2002.